What is Cosyntropin?
Cosyntropin is a synthetic ACTH fragment used in adrenal testing. The selected research paper examined a separate experimental obstetric application after accidental dural puncture.
Biological role or research focus
Adrenal signaling and experimental obstetric use.
This is a small study in a specific procedural setting. It does not establish broad headache treatment, and the prevention results should not be confused with treating an existing headache.
Role reference: Cosyntropin for prophylaxis against postdural puncture headache after accidental dural puncture. · 2010 ↗
Names you may encounter
Tetracosactide · ACTH 1–24
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic ACTH fragment
- Research focus
- Adrenal signaling and experimental obstetric use
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Cosyntropin FDA approved?
- Yes. Cortrosyn (NDA 016750, approved 1970) and generic cosyntropin. Source ↗
- Is Cosyntropin safe?
- Approved diagnostic hormone used to test adrenal gland function; the main risk is an allergic reaction, and some medicines can distort the test result. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Cosyntropin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.2 Corticotrophins and their releasing factors). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Post-dural-puncture headache prophylaxis study (2010) | Human randomized trial | 90 parturients after accidental dural puncture, studied after delivery. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2010
Post-dural-puncture headache prophylaxis study
Did prophylaxis reduce headache after accidental dural puncture?
- Population / model
- 90 parturients after accidental dural puncture, studied after delivery.
- Study design
- Randomized comparison of cosyntropin with saline for prevention of post-dural-puncture headache.
- Main finding
- Headache occurred in 33% versus 68.9%; epidural blood patches were required in 11.1% versus 28.9%. Among patients who developed headache, severity and duration were not significantly different.
- Limits & context
- This is a small study in a specific procedural setting. It does not establish broad headache treatment, and the prevention results should not be confused with treating an existing headache.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
23 registered studies name Cosyntropin as an intervention; 7 are recruiting or under way, 0 have not started recruiting yet, 10 completed and 6 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 23 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Congenital adrenal hyperplasia. ↗
Lancet (London, England) · 2017 Nov 11 · Journal Article, Review
Corticotroph deficiency. ↗
Annales d'endocrinologie · 2012 Apr · Journal Article, Review
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. ↗
Clinical and translational science · 2024 Aug · Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Read available full text ↗
Outcomes After Unilateral Adrenalectomy in Asymmetrical Bilateral Primary Aldosteronism. ↗
Hypertension (Dallas, Tex. : 1979) · 2025 Oct · Journal Article
Risks & interactions
Approved diagnostic hormone used to test adrenal gland function; the main risk is an allergic reaction, and some medicines can distort the test result.
Safety comes from FDA-approved labeling (Cortrosyn). Listed side effects come mainly from voluntary postmarketing reports, so how often they occur is not known.
Take extra care with: Liver problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with a past allergic reaction to cosyntropin or any ingredient (reactions have included anaphylaxis)
Interactions
- Glucocorticoid steroids and spironolactone: can falsely raise cortisol results
- Estrogen-containing drugs, including birth control pills: can raise total cortisol and skew results
- Conditions that change cortisol-binding protein, such as cirrhosis or nephrotic syndrome: can make results inaccurate
Serious risks
- Allergic reactions, including anaphylaxis
- Inaccurate cortisol results that could lead to a wrong diagnosis of adrenal insufficiency
Common side effects
- rash
- slow or fast heartbeat
- high blood pressure
- swelling of the legs or ankles
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Cortrosyn (cosyntropin) prescribing information ↗
What the featured evidence can tell us
Clinical administration and interpretation depend on the indication and exact preparation. This study does not establish safety for unsupervised use or prolonged exposure.
Source: DailyMed · Cosyntropin prescribing information ↗
Identity, route, and evidence limits
This is a small study in a specific procedural setting. It does not establish broad headache treatment, and the prevention results should not be confused with treating an existing headache.
Official product context · checked October 4, 2026
The label discusses hypersensitivity and inaccurate diagnostic results, including effects of other medicines on cortisol measurements. A biochemical test result requires interpretation in its clinical setting.
Source: DailyMed · Cosyntropin prescribing information ↗
Regulatory status
- U.S. FDA approval
- Approved
Cortrosyn (NDA 016750, approved 1970) and generic cosyntropin; diagnostic agent for adrenocortical insufficiency. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.2 Corticotrophins and their releasing factors
Named explicitly as "tetracosactide" (cosyntropin). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
The linked U.S. label identifies cosyntropin as a diagnostic agent, used with other tests to screen for adrenocortical insufficiency in adults and children. The headache-prevention study on this page investigates a different use and does not redefine the labeled indication.
The featured trial is not a study establishing adrenal-test protocols. It examines post-dural-puncture headache prevention in a particular obstetric setting; it should not be presented as a general headache indication.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Cosyntropin works
ACTH-related signaling stimulates the adrenal cortex. Its diagnostic use and the experimental headache-prevention question in this paper are distinct contexts.
Molecular structure
Questions worth asking
- Does this paper establish a general headache treatment?
- What population, comparator, and route were actually studied?
- This is a small study in a specific procedural setting. It does not establish broad headache treatment, and the prevention results should not be confused with treating an existing headache.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does this paper establish a general headache treatment?
No. It tested prevention following accidental dural puncture in an obstetric population. Other causes and treatment settings require separate evidence.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
